Condition
Antiplatelet Drug
Total Trials
5
Recruiting
1
Active
2
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 30/100
Termination Rate
0.0%
0 terminated out of 5 trials
Late-Stage Pipeline
40%
2 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
4Total
Not Applicable (1)
P 1 (1)
P 4 (2)
Trial Status
Active Not Recruiting1
Not Yet Recruiting1
Unknown1
Recruiting1
Suspended1
Clinical Trials (5)
Showing 5 of 5 trials
NCT06269432Phase 4Recruiting
Precise Antiplatelet THerapy Guided by Platelet Aggregation Function in Ischemic STROKE（PATH-STROKE）
NCT06243133Phase 4Not Yet Recruiting
Pair Antiplatelet THerapy in Ischemic Stroke With Intracranial Artery Stenosis
NCT04971356Not ApplicableActive Not RecruitingPrimary
1-month DAPT Plus 5-month Ticagrelor Monotherapy Versus 12-month DAPT in Patients With Drug-coated Balloon
NCT05852197Unknown
Effect of Anticoagulant Drug Intervention on Postoperative MALE and MACE in Patients With PAD
NCT04404790Phase 1SuspendedPrimary
Antiplatelet Thrombolysin (Anfibatide) Phase 1 Clinical Trial in Healthy Volunteers
Showing all 5 trials